Available from: http://www. ladocumentationfrancaise.fr/var/storage/rapports-publics, 2004. ,
HAS (2013) Decision no 2013 of the HAS College related to the significant impact on the health insurance expenses, triggering the medico-economic evaluation of the products claiming ASMR or ASA levels from level I to III Available from: http://hassante.fr/portail/jcms/c_1647592/fr/decision-n20130111/dc/seesp- du-18-septembre-2013-du-college-de-la-has-relatif-a-limpact- significatif-sur-les-depenses-de-lassurance-maladie-declenchantlevaluation-medico-economique-des-produits-revendiquant, 1116. ,
Rapport de presentation Available from: http://www.has-sante.fr/portail/jcms/c_1627029/fr/rapport-de- presentation-type, 2015. ,
New drug regulations in France: what are the impacts on market access? Part 2 ??? impacts on market access and impacts for the pharmaceutical industry, Journal of Market Access & Health Policy, vol.11, issue.1, p.20892, 2013. ,
DOI : 10.1186/1472-6963-11-259
The HAS in the new health environment in France and Europe. 2012 Available from: http://www. amips.fr/media, p.pdf, 2015. ,
Modelling in Ecomomic Evaluation: An Unavoidable Fact of Life, Health Economics, vol.6, issue.3, pp.217-244, 1997. ,
DOI : 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W
Funding, Health Technology Assessment, vol.19, issue.14, pp.1-503, 2015. ,
DOI : 10.3310/hta19140